CsnB enhances Nur77-mediated tumor inhibition by downregulating IRF1 expression, and pharmacological Nur77 stimulation with CsnB significantly enhances anti-PD-1 immunotherapy efficacy in a mouse tumor model. The gene discussed is NR4A1; the disease is neoplasm.